August 17, 2022 | 12:15 pm ET  

 

Dr. Jason Coleman will explore how to accelerate development and manufacturing of novel lipid nanoparticle(LNP)-based therapeutics through scalable microfluidic technologies, off-the-shelf reagents, and a novel lipid library. 
 

Given the complexities and challenges for developing genomic cancer vaccines, it is critical to have a scalable and robust manufacturing platform for the development of non-viral delivery methods. 

This talk will share insights into a scalable manufacturing platform for RNA-LNPs and the use of this technology for the development of a high-potency self-amplifying (saRNA) LNP vaccine. We will also highlight key considerations for the development of a LNP vaccine drug product. 

Presentation Abstract

 

RNA can be designed to silence, express, and edit specific genes providing a flexible and powerful approach to treating diseases. While the development of RNA vaccines for COVID-19 is an extraordinary achievement, it has revealed that rapid development and scaling up – as well as access to necessary technologies – are required to keep up with emerging variants and to help usher in the new era RNA medicines in other therapeutic areas of unmet medical need. 
 
Precision NanoSystems has developed a Genomic Medicine Toolbox for the end-to-end development and manufacturing of RNA-lipid nanoparticles (RNA-LNPs). The toolbox comprises an RNA drug substance platform, a lipid nanoparticle drug delivery platform, and a microfluidic manufacturing platform. These tools are made accessible to scientists of different backgrounds by leveraging in-house expertise in RNA-LNP formulation, manufacturing, process and analytical development to engineer both our know-how and ease of use into them. In this presentation, we show data to demonstrate the versatility of the toolbox for the rapid development of vaccines, gene therapies and cell therapies.